Empesertib

DB19473InvestigationalSmall molecule

Empesertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Empesertib is a serine/threonine kinase inhibitor. Empesertib is under investigation in clinical... Empesertib is under investigation in clinical trial NCT02138812 (Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel).

Mechanism: Pharmacologically active on Dual specificity protein kinase TTK
Curator reviewed
Formula / weight: C₂₉H₂₆FN₅O₄S · 559.62 g/mol (avg)
Code names: (-)-BAY-1161909 · MPS1-IN-5

Resolves to

Compound

UNII02Y3Z2756MCAS1443763-60-7ChEMBLCHEMBL4303241ChEBI757653PubChem71599640

Structure

InChIKeyNRJKIOCCERLIDG-GOSISDBHSA-NSMILESCOC1=CC(=CC=C1NC1=NN2C=C(C=CC2=N1)C1=CC=C(NC(=O)[C@H](C)C2=CC=C(F)C=C2)C=C1)S(C)(=O)=O

Targets

P33981TTK

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Empesertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account